Michael R. McDevitt is an Associate Attending Radiochemist in the Departments of Medicine and Radiology at Memorial Hospital and an Associate Laboratory Member in the Sloan Kettering Institute. He specializes in the development of targeted radiolabeled drug constructs. Radioimmunoconstructs are drugs that combine antibodies and radionuclides for therapeutic and imaging applications in the treatment of cancer. Recently, he has been investigating the integration of nanomaterials such as carbon nanotubes into his drug design paradigm. His research involves the investigation of new chemistry, radiochemistry, biological activity, pharmacokinetics, safety, stability, and the translation of novel drug construct candidates into the clinic.
After receiving his PhD degree in chemistry in 1985 from Case Western Reserve University, Dr. McDevitt worked in biotechnology and joined Memorial Sloan Kettering in 1995. In 2004, he received a master’s degree in chemical engineering from The City University of New York. He is also a member of Memorial Sloan Kettering’s Brain Tumor Center and Nanotechnology Center.
- Clinical Expertise: Radiolabeled Monoclonal Antibodies for use in Clinical Trials
- Languages Spoken: English
- Education: PhD (Chemistry), Case Western Reserve University; ME (Chemical Engineering), The City College of New York
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more